FYL Rapid Test (Urine)

Product description:

A rapid test for the qualitative detection of FYL in human urine. For professional in vitro medical and diagnostic use only.

Intended use:

The FYL rapid test panel (Fentanyl) (Urine) is a rapid immunochromatographic test for the qualitative detection of Norfentanyl, a metabolite of Fentanyl. Fentanyl is a potent narcotic analgesic whose abuse can lead to habituation or dependence, and it is primarily a mu-opioid agonist. Norfentanyl is also used as an adjunct to general anesthetics and as an induction and maintenance anesthetic.

Main features:

• 
  Method: Rapid immunochromatographic test.
  


• 
  Detection threshold: 20 ng/mL of Norfentanyl in urine.
  


• 
  Response time: Accurate and rapid results.
  


• 
  Result confirmation: To obtain a confirmed analytical result, it is necessary to use a more specific alternative chemical method such as Gas Chromatography/Mass Spectrometry (GC/MS).
  


• 
  Clinical considerations: Professional clinical judgment is required to correctly interpret the results, especially in the case of preliminary positive results.
  

Summary:

Fentanyl is a potent narcotic analgesic that acts as a stimulant of mu-opioid receptors. It is listed in the "Single Convention on Narcotic Drugs" of the United Nations of 1961 and is commonly used to treat moderate to severe pain. Prolonged abuse of Fentanyl can lead to addiction and withdrawal syndrome, with effects such as ataxia and irritability. Fentanyl addicts have a higher risk of HIV infection and overdose than amphetamine addicts.

The FYL Rapid Test Panel (Urine) is a rapid screening test that can be performed without instruments. It uses a monoclonal antibody to selectively detect elevated levels of Norfentanyl in urine, providing a positive result when the concentration exceeds 20 ng/mL.

Test principle:

The FYL rapid test panel (urine) is based on the principle of competitive binding. The drugs present in the urine sample compete with the drug conjugate for the antibody binding sites. During the test, the urine sample migrates upward by capillary action. If the concentration of Fentanyl in the sample is below 20 ng/mL, it will not saturate the binding sites of the antibody-coated particles in the test device, resulting in a visible colored line in the test line region. If the concentration of FYL exceeds 20 ng/mL, it will saturate all anti-FYL antibody binding sites, preventing the formation of a colored line.

As a procedural control, a colored line will always appear in the control line area, indicating that the correct sample volume has been added and that membrane migration has occurred properly.